In the study by Nicolazzo et al., CTC monitoring at three prespecified timepoints (after 1, 3 and 6 months from the beginning of treatment) during nivolumab treatment, allowed to divide patients with NSCLC into two subgroups according to PD-L1 expression [29]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.